Overexpression of prostaglandin EP 3 receptors activates calcineurin and promotes hypertrophy in the murine heart

Cardiovascular Research

Volumn 81, Issue 2, 2009, Pages 310-318

  Meyer Kirchrath, Jutta ^a   Martin, Melanie ^a   Schooss, Christina ^a   Jacoby, Christoph ^b   Flögel, Ulrich ^b   Marzoll, Andrea ^a   Fischer, Jens W ^c   Schrader, Jürgen ^b   Schrör, Karsten ^a   Hohlfeld, Thomas ^a  

^a UNIVERSITY HOSPITAL DÜSSELDORF   (Germany)

^b HEINRICH HEINE UNIVERSITY   (Germany)

^c UNIVERSITY HOSPITAL ESSEN   (Germany)

Author keywords

Calcineurin; EP 3 receptor; Hypertrophy; NFAT; Prostaglandins

Indexed keywords

CALCINEURIN; CELL MARKER; CYCLIC AMP; G PROTEIN COUPLED RECEPTOR; PROSTAGLANDIN EP3 RECEPTOR; PROSTAGLANDIN RECEPTOR; UNCLASSIFIED DRUG; EP3 PROTEIN, MOUSE; INHIBITORY GUANINE NUCLEOTIDE BINDING PROTEIN; PROSTAGLANDIN E RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; EXTRACELLULAR MATRIX; GENE OVEREXPRESSION; HEART FUNCTION; HEART HYPERTROPHY; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE ENDDIASTOLIC PRESSURE; HEART LEFT VENTRICLE FUNCTION; HEART LEFT VENTRICLE MASS; HEART MUSCLE CELL; HEART VENTRICLE REMODELING; HEART VOLUME; HISTOPATHOLOGY; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROTEIN ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TRANSGENIC MOUSE; WILD TYPE; ANIMAL; BIOSYNTHESIS; CARDIOMEGALY; PATHOLOGY; PHYSIOLOGY; TRANSGENE;

ANIMALS; CALCINEURIN; CARDIOMEGALY; CYCLIC AMP; GTP-BINDING PROTEIN ALPHA SUBUNITS, GI-GO; MAGNETIC RESONANCE IMAGING; MICE; MYOCYTES, CARDIAC; RECEPTORS, PROSTAGLANDIN E; SIGNAL TRANSDUCTION; TRANSGENES; VENTRICULAR FUNCTION, LEFT; VENTRICULAR REMODELING;

EID: 58449119127     PISSN: 00086363     EISSN: 17553245     Source Type: Journal    
DOI: 10.1093/cvr/cvn312     Document Type: Article

References (42)

1. Valen G. Cellular signalling mechanisms in adaptation to ischemia-induced myocardial damage. Ann Med 2003;35:300-307.
2. Schrör K. Eicosanoid generation and effects in cardiac muscle and coronary vessels. In: Curtis-Prior P (ed.) The Eicosanoids. Chichester: Wiley; 2004, 393-404.
3. 2 on myocardial infarct size after coronary occlusion in conscious dogs. Circ Res 1981;49:685-700.
4. 3) in the nonischemic and ischemic pig heart. Circ Res 1997;81:765-773.
5. 3 receptors in the reperfused ischemic pig heart. J Mol Cell Cardiol 2000;32:285-296.
6. Thiemermann C, Zacharowski K. Selective activation of E-type prostanoid(3)-receptors reduces myocardial infarct size. A novel insight into the cardioprotective effects of prostaglandins. Pharmacol Ther 2000;87:61-67.
7. Martin M, Meyer-Kirchrath J, Kaber G, Jacoby C, Flögel U, Schrader J et al. Cardiospecific overexpression of the prostaglandin EP3 receptor attenuates ischemia-induced myocardial injury. Circulation 2005;112:400-406.
8. Hashimoto N, Watanabe T, Ikeda Y, Yamada H, Taniguchi S, Mitsui H et al. Prostaglandins induce proliferation of rat hepatocytes through a prostaglandin E2 receptor EP3 subtype. Am J Physiol 1997;272:G597- G604.
9. Chell SD, Witherden IR, Dobson RR, Moorghen M, Herman AA, Qualtrough D et al. Increased EP4 receptor expression in colorectal cancer progression promotes cell growth and anchorage independence. Cancer Res 2006;66:3106-3113.
10. 2 in cardiac myocytes. Hypertension 2002;39:382-388.
11. Mendez M, LaPointe MC. PGE2-induced hypertrophy of cardiac myocytes involves EP4 receptor-dependent activation of p42/44 MAPK and EGFR transactivation. Am J Physiol Heart Circ Physiol 2005;288:H2111- H2117.
12. 2 and cyclic adenosine 3′-5′ monophosphate levels in hypertrophied rat heart. Biol Res 1992;25:85-89.
13. Saito T, Rodger IW, Hu F, Shennib H, Giaid A. Inhibition of cyclooxygenase-2 improves cardiac function in myocardial infarction. Biochem Biophys Res Commun 2000;273:772-775.
14. LaPointe MC, Mendez M, Leung A, Tao Z, Yang XP. Inhibition of cyclooxygenase-2 improves cardiac function after myocardial infarction in the mouse. Am J Physiol Heart Circ Physiol 2004;286:H1416-H1424.
15. Narumiya S, Sugimoto Y, Ushikubi F. Prostanoid receptors: structures, properties, and functions. Physiol Rev 1999;79:1193-1226.
16. 3 subtype generated by alternative messenger RNA splicing: multiple second messenger systems and tissue-specific distributions. Mol Pharmacol 1995;48:869-879.
17. Namba T, Sugimoto Y, Negishi M, Irie A, Ushikubi F, Kakizuka A et al. Alternative splicing of C-terminal tail of prostaglandin E receptor subtype EP3 determines G-protein specificity. Nature 1993;365:166- 170.
18. 3-receptor from porcine heart. Adv Exp Med Biol 1997;433:119-122.
19. Westermann D, Mersmann J, Melchior A, Freudenberger T, Petrik C, Schaefer L et al. Biglycan is required for adaptive remodeling after myocardial infarction. Circulation 2008;117:1269-1276.
20. Burke AP, Kolodgie FD, Farb A, Weber DK, Malcom GT, Smialek J et al. Healed plaque ruptures and sudden coronary death: evidence that subclinical rupture has a role in plaque progression. Circulation 2001;103:934-940.
21. Jacoby C, Molojavyi A, Flögel U, Merx M, Ding Z, Schrader J. Direct comparison of magnetic resonance imaging and conductance microcatheter in the evaluation of left ventricular function in mice. Basic Res Cardiol 2006;101:87-95.
22. Xiao CY, Yuhki K, Hara A, Fujino T, Kuriyama S, Yamada Tet al. Prostaglandin E2 protects the heart from ischemia-reperfusion injury via its receptor subtype EP4. Circulation 2004;109:2462-2468.
23. Qian JY, Harding P, Liu Y, Shesely E, Yang XP, LaPointe MC. Reduced cardiac remodeling and function in cardiac-specific EP4 receptor knockout mice with myocardial infarction. Hypertension 2008;51:560-566.
24. s activity. FEBS Lett 1996;386:165-168.
25. Remme WJ. The sympathetic nervous system and ischaemic heart disease. Eur Heart J 1998;19(Suppl. F):F62-F71.
26. Hara A, Abiko Y. Role of the sympathetic nervous system in the ischemic and reperfused heart. EXS 1996;76:285-297.
27. Baker AJ, Redfern CH, Harwood MD, Simpson PC, Conklin BR. Abnormal contraction caused by expression of G(i)-coupled receptor in transgenic model of dilated cardiomyopathy. Am J Physiol Heart Circ Physiol 2001;280:H1653-H1659.
28. Bonacci TM, Ghosh M, Malik S, Smrcka AV. Regulatory interactions between the amino terminus of G-protein betagamma subunits and the catalytic domain of phospholipase Cbeta2. J Biol Chem 2005;280:10174-10181.
29. Molkentin JD. Calcineurin-NFAT signaling regulates the cardiac hypertrophic response in coordination with the MAPKs. Cardiovasc Res 2004;63:467-475.
30. Wilkins BJ, Molkentin JD. Calcium-calcineurin signaling in the regulation of cardiac hypertrophy. Biochem Biophys Res Commun 2004;322:1178- 1191.
31. Molkentin JD, Lu JR, Antos CL, Markham B, Richardson J, Robbins J et al. A calcineurin-dependent transcriptional pathway for cardiac hypertrophy. Cell 1998;93:215-228.
32. Diedrichs H, Chi M, Boelck B, Mehlhorn U, Schwinger RH. Increased regulatory activity of the calcineurin/NFAT pathway in human heart failure. Eur J Heart Fail 2004;6:3-9.
33. Kurosu H, Maehama T, Okada T, Yamamoto T, Hoshino S, Fukui Y et al. Heterodimeric phosphoinositide 3-kinase consisting of p85 and p110β is synergistically activated by the βγ subunits of G proteins and phosphotyrosyl peptide. J Biol Chem 1997;272:24252-24256.
34. βγ induced activation of class I phosphoinositide 3-kinase isoforms beta and gamma. J Biol Chem 1999;274:29311- 29317.
35. Frey N, Olson EN. Cardiac hypertrophy: the good, the bad, and the ugly. Annu Rev Physiol 2003;65:45-79.
36. Zou Y, Komuro I, Yamazaki T, Kudoh S, Uozumi H, Kadowaki T et al. Both Gs and Gi proteins are critically involved in isoproterenol-induced cardiomyocyte hypertrophy. J Biol Chem 1999;274:9760-9770.
37. Swynghedauw B. Molecular mechanisms of myocardial remodeling. Physiol Rev 1999;79:215-262.
38. Brower GL, Gardner JD, Forman MF, Murray DB, Voloshenyuk T, Levick SP et al. The relationship between myocardial extracellular matrix remodeling and ventricular function. Eur J Cardiothorac Surg 2006;30:604-610.
39. Burlew BS, Weber KT. Connective tissue and the heart. Functional significance and regulatory mechanisms. Cardiol Clin 2000;18:435- 442.
40. Weis SM, Zimmerman SD, Shah M, Covell JW, Omens JH, Ross J Jr et al. A role for decorin in the remodeling of myocardial infarction. Matrix Biol 2005;24:313-324.
41. Yamamoto K, Kusachi S, Ninomiya Y, Murakami M, Doi M, Takeda K et al. Increase in the expression of biglycan mRNA expression co-localized closely with that of type I collagen mRNA in the infarct zone after experimentally induced myocardial infarction in rats. J Mol Cell Cardiol 1998;30:1749-1756.
42. Koitabashi N, Arai M, Kogure S, Niwano K, Watanabe A, Aoki Y et al. Increased connective tissue growth factor relative to brain natriuretic peptide as a determinant of myocardial fibrosis. Hypertension 2007;49:1120-1127.